Physix Frontier · News Briefing Card (TMTPost · Nov 17, 2026)
Orbis Medicines uses AI closed-loop process to develop oral macrocyclic drugs
KEY FACTS
- Swiss company Orbis Medicines was founded in 2021 and develops AI-driven high-throughput drug discovery processes.
- The process uses a laboratory closed-loop model that can synthesize and analyze about 100,000 macrocyclic compounds within weeks.
- The company screens initial active molecules from a DNA-encoded library of nearly 100 billion compounds.
- In September 2026 it reached a cardiovascular and metabolic drug collaboration agreement with Novo Nordisk worth up to $1.4 billion.
- In January 2025 the company completed a €90 million Series A financing round led by NEA.
KEY DATA
Nearly 100 billionNumber of compounds in DNA-encoded library
Up to about 100,000Number of compounds synthesized and analyzed per round
$1.4 billionMaximum value of Novo Nordisk collaboration agreement
€90 millionSeries A financing amount
PHYSIX OBSERVATION
Oral macrocyclic drugs have long been stuck on permeability and stability. Orbis uses an AI closed loop to compress design-to-validation into weeks, which amounts to diluting trial-and-error costs. Novo Nordisk's $1.4 billion bet shows that big pharma recognizes this route, but whether the platform can produce clinical candidates remains the key test.
Source: TMTPost report
Physix Frontier